Abstract: A method for sterilizing contact lenses and especially hydrophilic (soft) contact lenses comprising contacting a contact lens for a period of time sufficient to sterilize the lens with a substantially isotonic, aqueous composition having a pH between 6-9 comprising about 0.01 to about 0.3 percent by weight of an ene-diol compound and from about 0.1 to about 25 ppm copper ion. Preferred ene-diol compounds are dihydroxyfumaric acid and dihydroxymaleic acid.

Abstract: A method for sterilizing contact lenses and especially hydrophilic (soft) contact lenses comprising contacting a contact lens for a period of time sufficient to sterilize the lens with a substantially isotonic, aqueous composition having a pH between 6-9 comprising about 0.01 to about 0.3 percent by weight of an ene-diol compound such as reductic acid and from about 0.1 to about 25 ppm copper ion.

Abstract: A method for sterilizing contact lenses and especially hydrophilic (soft) contact lenses comprising contacting a contact lens for a period of time sufficient to sterilize the lens with a substantially isotonic, aqueous composition having a pH between about 6-9 comprising about 0.01 to about 0.3 percent by weight of an ene-diol compound and from about 0.1 to about 25 ppm copper ion. Preferred ene-diol compounds are ascorbic acid and dihydroxymaleic acid.

Abstract: A method for treating mouth pain by administering to a human having such pain an effective mouth pain reducing amount of dextromethorphan, preferably as the hydrobromide.

Abstract: Pharmaceutical compositions containing triethylenetetramine (trien) useful in treating skin disorders. Trien may be used alone to treat inflammation of the skin or may be combined with additional anti-inflammatory, anti-infective or antimitotic agents in the treatment of skin disorders such as acne, psoriasis, seborrhea and dermatitis. Trien also forms a clear solution or gel with zinc pyrithione.

Abstract: A method for temporarily reducing pain in animals including humans, and especially pain associated with gastrointestinal dysfunction, by administering to an animal having pain an effective, pain reducing amount of dextromethorphan, preferably as the hydrobromide.

Abstract: There is disclosed a method of improvement of dyeing fibers by utilizing in the dyeing process, an effective, dye-enhancing amount of a textile auxiliary having the structural formula ##STR1## wherein R' is H or a lower alkyl group having 1-4 carbon atoms, n is O or a positive integer from 1-11 and R is an alkyl group (straight or branch chain) having 1-18 carbon atoms or aryl group, e.g., phenyl. The compounds disclosed herein enhance dye penetration of fibers and allow the dyeing process to take place at lower temperatures in less time.

Abstract: There is disclosed a method of treatment of inflammation in humans and animals comprising contacting the inflamed area with an effective, anti-inflammatory amount of 1-dodecylazacycloheptan-2-one.

Abstract: A process for inhibiting platelet aggregation or thrombus formation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## WHEREIN X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, Y is H, alkyl, dialkylaminoethyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R, and R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##STR2## NHCOR.sub.1, NR.sub.1 R.sub.2 or ##STR3## where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl; R, R.sub.1 and R.sub.2 being the same or different and n is 0-5; and pharmaceutically acceptable salts thereof, to in vivo and in vitro platelet systems.

Abstract: A process for inhibiting platelet aggregation or thrombus formation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## WHEREIN X is an alkyl or alkenyl chain having 2-8 carbon atoms, one of which carbon atoms may be in the form of a carbonyl group, Y is H, alkyl, dialkylaminoethyl, aryl, aralkyl or aryl and aralkyl substituted with one or more R, and R is H, lower alkyl, lower alkoxy, halogen, CF.sub.3, NO.sub.2, OH, CN, COOR.sub.1, ##STR2## NHCOR.sub.1, NR.sub.1 R.sub.2 or ##STR3## where R.sub.1 and R.sub.2 are each selected from the group consisting of H and lower alkyl; R, R.sub.1 and R.sub.2 being the same or different, T is selected from the group consisting of O, NH, S and CH.sub.2 with the proviso that only one T is O, Z is 0 or 1 and n is 0-5; and pharmaceutically acceptable salts thereof, to in vivo and in vitro platelet systems.